Literature DB >> 9614323

Modelling the chloroquine chemotherapy of falciparum malaria: the value of spacing a split dose.

M B Hoshen1, W D Stein, H Ginsburg.   

Abstract

We have attempted to provide a rational basis for improving the protocols for chemotherapy of malaria. We model the regression of parasitaemia by Plasmodium falciparum, its subsequent elimination from the body, or recrudescence, for populations of cells treated with chloroquine. Our model assumes that drug forms a complex with some receptor in the parasite and that parasites possessing this complex die at a defined rate. We take into account that chloroquine is eliminated exponentially from the body. We show how the parameters of the model can be derived from observations in the field. The model correctly predicts the effects of drug dose, degree of initial parasitaemia, rate of parasite multiplication and degree of drug resistance to chloroquine chemotherapy. The level of parasitaemia will reduce to a minimum at sufficiently high concentrations of chloroquine, but only if the parasitaemia is reduced to below that of 1 parasite per infected person will a cure of malaria be obtained. Otherwise, recrudescence will, sooner or later, occur. We show that, even for drug-resistant malaria, if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of chloroquine being reached.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9614323     DOI: 10.1017/s0031182098002480

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  18 in total

1.  Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin.

Authors:  Toufigh Gordi; Rujia Xie; William J Jusko
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

2.  Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure.

Authors:  Katherine Winter; Ian M Hastings
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

Review 3.  Making the most of clinical data: reviewing the role of pharmacokinetic-pharmacodynamic models of anti-malarial drugs.

Authors:  Julie A Simpson; Sophie Zaloumis; Alysha M DeLivera; Ric N Price; James M McCaw
Journal:  AAPS J       Date:  2014-07-24       Impact factor: 4.009

4.  Mechanism-based model of parasite growth and dihydroartemisinin pharmacodynamics in murine malaria.

Authors:  Kashyap Patel; Kevin T Batty; Brioni R Moore; Peter L Gibbons; Jürgen B Bulitta; Carl M Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

Review 5.  Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challenges.

Authors:  Kashyap Patel; Julie A Simpson; Kevin T Batty; Sophie Zaloumis; Carl M Kirkpatrick
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

6.  Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance.

Authors:  J A Simpson; E R Watkins; R N Price; L Aarons; D E Kyle; N J White
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

7.  Altering Antimalarial Drug Regimens May Dramatically Enhance and Restore Drug Effectiveness.

Authors:  Katherine Kay; Eva Maria Hodel; Ian M Hastings
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

8.  Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development.

Authors:  Sophie Zaloumis; Andrew Humberstone; Susan A Charman; Ric N Price; Joerg Moehrle; Javier Gamo-Benito; James McCaw; Kris M Jamsen; Katherine Smith; Julie A Simpson
Journal:  Malar J       Date:  2012-08-30       Impact factor: 2.979

9.  Dynamics of immune response and drug resistance in malaria infection.

Authors:  David Gurarie; F Ellis McKenzie
Journal:  Malar J       Date:  2006-10-11       Impact factor: 2.979

10.  Improving the role and contribution of pharmacokinetic analyses in antimalarial drug clinical trials.

Authors:  Katherine Kay; Eva Maria Hodel; Ian M Hastings
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.